Lee J, Jung E, Lee J, Huh S, Boo Y C, Hyun C G, Kim Y-S, Park D
Biospectrum Life Science Institute, Gyunggi Do, Korea.
Br J Dermatol. 2007 Aug;157(2):242-8. doi: 10.1111/j.1365-2133.2007.07934.x.
Increased production and accumulation of melanin is characteristic of a large number of skin diseases, including acquired hyperpigmentation such as melasma, postinflammatory melanoderma and solar lentigo. Thus, there is a increasing need for the development of depigmenting agents.
To evaluate the depigmenting capacity of 2,5-dimethyl-4-hydroxy-3(2H)-furanone (DMHF) and to elucidate the mechanisms by which it inhibits alpha-melanocyte-stimulating hormone (alpha-MSH)-induced melanogenesis in B16 melanoma cells in vitro.
Several experiments were performed in B16 melanoma cells. We studied melanin content, tyrosinase activity and cAMP production, and performed cAMP response element (CRE) luciferase reporter assay and Western blots for proteins involved in melanogenesis.
The melanin content and tyrosinase activity induced by alpha-MSH were inhibited significantly by DMHF. To clarify the mechanism of the depigmenting property of DMHF, we examined the involvement of DMHF in cAMP signalling induced by alpha-MSH. In CRE luciferase reporter assay, CRE reporter activation induced by alpha-MSH was inhibited by DMHF. Additionally, although DMHF did not inhibit cAMP production by alpha-MSH, both CRE binding protein (CREB) phosphorylation and the reduction of glycogen synthase kinase-3beta phosphorylation by alpha-MSH were blocked by DMHF. These data suggest that DMHF inhibits the downstream step of cAMP production induced by alpha-MSH, consequently inhibiting melanogenesis. This suggestion was further confirmed by the fact that the increased production levels of microphthalmia-associated transcription factor, tyrosinase and tyrosinase-related protein-1 induced by alpha-MSH were all reduced by DMHF in B16 melanoma cells.
Our study shows that DMHF inhibits alpha-MSH-induced melanogenesis by suppressing CREB phosphorylation, which is induced by protein kinase A, and suggests that DMHF may be an effective inhibitor of hyperpigmentation.
黑色素生成增加及积累是多种皮肤病的特征,包括获得性色素沉着,如黄褐斑、炎症后黑变病和日光性雀斑。因此,对开发色素沉着抑制剂的需求日益增加。
评估2,5 - 二甲基 - 4 - 羟基 - 3(2H)-呋喃酮(DMHF)的色素沉着抑制能力,并阐明其在体外抑制α-黑素细胞刺激激素(α-MSH)诱导的B16黑色素瘤细胞黑色素生成的机制。
在B16黑色素瘤细胞中进行了多项实验。我们研究了黑色素含量、酪氨酸酶活性和cAMP生成,并进行了cAMP反应元件(CRE)荧光素酶报告基因测定以及对参与黑色素生成的蛋白质进行蛋白质免疫印迹分析。
DMHF显著抑制了α-MSH诱导的黑色素含量和酪氨酸酶活性。为阐明DMHF色素沉着抑制特性的机制,我们研究了DMHF在α-MSH诱导的cAMP信号传导中的作用。在CRE荧光素酶报告基因测定中,DMHF抑制了α-MSH诱导的CRE报告基因激活。此外,虽然DMHF不抑制α-MSH诱导的cAMP生成,但DMHF阻断了α-MSH诱导的CRE结合蛋白(CREB)磷酸化以及糖原合酶激酶-3β磷酸化的减少。这些数据表明,DMHF抑制了α-MSH诱导的cAMP生成的下游步骤,从而抑制黑色素生成。B16黑色素瘤细胞中α-MSH诱导的小眼畸形相关转录因子、酪氨酸酶和酪氨酸酶相关蛋白-1生成水平的增加均被DMHF降低,这一事实进一步证实了这一推测。
我们的研究表明,DMHF通过抑制蛋白激酶A诱导的CREB磷酸化来抑制α-MSH诱导的黑色素生成,并提示DMHF可能是一种有效的色素沉着过度抑制剂。